Hepaglide 0.25mg Injection

Q1: What is Hepaglide 0.25mg used for?

Hepaglide 0.25mg is the initiation dose of injectable semaglutide from Zydus Healthcare, used for the first 4 weeks of GLP-1 therapy to establish tolerability before escalation to the therapeutic 0.5mg dose for weight management or type 2 diabetes.

Q2: What makes Hepaglide different from other Indian semaglutide injections?

Hepaglide is manufactured by Zydus Healthcare, part of Zydus Lifesciences — one of India's largest global pharma companies with multiple US FDA-approved manufacturing sites. Zydus' reputation for quality and regulatory compliance sets Hepaglide apart in the Indian generic semaglutide market.

Q3: Is Zydus Healthcare a reliable pharmaceutical manufacturer?

Zydus Healthcare is a subsidiary of Zydus Lifesciences Ltd. (formerly Cadila Healthcare), India's fourth-largest pharmaceutical company by revenue. It has multiple US FDA, UK MHRA, and WHO-GMP approved facilities and exports to over 100 countries.

Q4: How does Hepaglide 0.25mg compare to Noveltreat 0.25mg?

Both contain semaglutide 0.25mg and work by the same mechanism. The key difference is the manufacturer — Zydus Healthcare vs Knoll Pharma. Both are DCGI-approved and bioequivalent to the originator product, offering equivalent clinical performance.

Q5: Can I start directly with a higher Hepaglide dose if I previously used Ozempic?

If you are transitioning from an equivalent dose of Ozempic (semaglutide), you may continue at your current dose rather than restarting at 0.25mg. Discuss this with your prescriber to determine the appropriate starting point.

Q6: How long does each Hepaglide 0.25mg pen last?

Each pen provides doses for a specific number of weeks depending on the pen capacity. Typically, a Hepaglide 0.25mg pen provides 4 doses for the 4-week initiation period. Confirm the number of doses per pen in your product packaging.

Q7: Can I inject Hepaglide into my upper arm by myself?

Self-injection into the outer upper arm is possible but more challenging than the abdomen or thigh. Many patients prefer to have a caregiver assist with upper arm injections. The abdomen and thigh are easier sites for self-administration.

Q8: What if I feel no effect at all from the 0.25mg dose?

The 0.25mg initiation dose is not intended to produce significant weight loss or glycaemic improvement — its purpose is solely to allow the body to adapt to semaglutide. Clinical effects build progressively with each dose escalation step.

Q9: Does Hepaglide 0.25mg require dose adjustment in the elderly?

No dose adjustment is required based on age alone. However, elderly patients are more susceptible to dehydration from GI side effects and should maintain good fluid intake. Renal function monitoring is advisable in this age group.

Q10: Can a patient with history of thyroid disease use Hepaglide?

Patients with autoimmune thyroid disease (Hashimoto's, Graves') are not specifically contraindicated from semaglutide. The contraindication applies only to medullary thyroid carcinoma or MEN2. Disclose your thyroid history to your prescriber.